[Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005858:Germany; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009313:National Health Programs / Q000331:legislation & jurisprudence*; D000077205:Pioglitazone; D016032:Randomized Controlled Trials as Topic; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone